NetworkNewsWire
Editorial Coverage: In a natural response to injury or
infection, the body produces chemicals that trigger the immune
system to release antibodies and proteins plus increase blood flow
to the afflicted area, which aids healing and produces
inflammation. However, the immune system and the inflammatory
processes have pernicious aspects far removed from beneficial
healing. In fact, inflammation has been directly linked to a wide
variety of physical and mental health maladies. Inflammation is
also a symptom of infectious diseases, implicated in noninfectious
diseases, and new findings show a causal relationship with
postsurgical trauma. Inflammatory diseases are recognized as the
most significant cause of death in the world, with more than
50% of all
deaths attributed to inflammation-related diseases. The
recognition of the connection between inflammation and disease
sparked a flurry of biotech research and a new generation of drug
development to treat previously untreatable disorders. World
renowned scientists that now lead 180 Life Sciences Corp.
(NASDAQ: ATNF) (180
Profile) pioneered the research and
development of one of the first anti-inflammatory therapeutics to
ever reach market, and today these drugs generate multiple billions
of dollars in annual sales. Critical to creation of some the most
important and profitable drugs ever on the market, the 180 team is
in hot pursuit of new anti-inflammatory blockbusters with active
programs in both preclinical and clinical studies. The world's
largest and most broadly based health-care company,
Johnson &
Johnson (NYSE: JNJ), owns Remicade (infliximab), a
blockbuster several times over with approved use in a range of
inflammatory diseases. The founders of 180
Life Sciences discovered the anti-TNF (tumor necrosis factor)
drug class that led to the development of Remicade and to a $4.9
billion merger between JNJ and Centocor Biotech. AbbVie
Inc. (NYSE: ABBV) owns Humira, an anti-TNF therapeutic
and top-selling drug in the world. The scientists at 180 Life
Sciences licensed the anti-TNF technology in development of Humira.
One of the world’s leading biotech’s, Amgen
Inc. (NASDAQ: AMGN), bought Celgene’s blockbuster
anti-inflammatory drug Otezla in 2019 for $13.4 billion in cash,
and Eli
Lilly (NYSE: LLY) recently announced a deal for Rigel
Pharmaceuticals’ autoimmune and inflammatory diseases treatment for
$960 million. In addition to delivering much-needed relief for
previously untreatable maladies, eye-popping sales and king-sized
acquisitions are likely to accelerate in the anti-inflammatory
space, as more new and highly effective drugs come to market.
- An estimated 50% of deaths are attributable to
inflammation-related diseases.
- Scientists at 180 Life Sciences are world-renowned pioneers of
anti-inflammatory research and drug development.
- Previous drug discoveries led to multibillion dollar
buyouts.
- 180 Life Sciences now focused on creating next generation
anti-inflammatory drugs.
Click here to view
the custom infographic of the 180 Life Sciences
Corp. editorial.
The Market
The global anti-inflammatory biologics market is expected to
reach nearly $150 billion
by 2027 and enjoy an 11% compound annual growth rate during the
period. Strong demand and increasing sales already exist in the
United States, and the demand for anti-inflammatory therapeutics is
poised to surge in Europe due to government support for the drugs
and favorable reimbursement policies. All the while, steadily
increasing R&D investment, as well as mergers and acquisitions
by biotech and pharmaceutical companies for development of
blockbuster biologics appear likely to continue to propel market
growth further in coming years.
Ongoing research and clinical trials for anti-tumor necrosis
factor (anti-TNF) antibodies in autoimmune inflammatory diseases
such as rheumatoid arthritis, psoriatic arthritis, plaque
psoriasis, ulcerative colitis and Crohn’s disease seem likely to
only add to market growth and expansion as new anti-TNF uses are
found. The wild card is that new findings implicate inflammation in
a variety of other disorders with high unmet medical need. Research
is ongoing and clinical trials are in progress with more planned
for later this year. With any success, market forecasts many have
to be adjusted substantially higher.
Anti-Inflammatory Pioneers
The founding team members at 180 Life
Sciences Corp. (NASDAQ: ATNF) are the recognized
pioneers of research and development in anti-inflammatory
therapeutics. 180 Life Sciences is a clinical-stage biotechnology
company that brings together the expertise of world-renowned
scientists to develop and test novel treatments for inflammation
and is currently working in both preclinical and clinical studies.
By leveraging the combined expertise of luminaries in therapeutics
from Oxford University, the Hebrew University and Stanford
University, the company is leading new research into solving the
complexities of inflammation to answer vast unmet medical
needs.
180 Life Sciences has active programs
developing novel drugs in separate areas of inflammation to
offer solutions to large market maladies that have no effective
therapies. The company is developing potential treatment for
arthritic conditions using synthetic cannabidiol analogs and is
also developing a treatment for ulcerative colitis in
ex-smokers.
180’s lead platform, fibrosis & anti-TNF, with its lead
clinical program in Phase 2b/3 stage, is led by Professor Sir Marc
Feldmann (executive co-chairman of 180 Life Sciences), a renowned
immunologist and pioneer of anti-TNF therapy, and Professor Jagdeep
Nanchahal, who has pioneered the treatment of fibrosis of the hand
(Dupuytren’s disease). The program is designed to address four
critical areas of inflammation to treat:
- Dupuytren’s Disease, a hand deformity that afflicts about 5% of
the population in the US and EU. 180 Life Sciences is conducting
the largest clinical trials for Dupuytren’s Disease and is in the
final stages of its phase 2b/3 human clinical trials for preventing
Dupuytren’s finger and hand contracture before it becomes severe
and permanent or requires surgery.
- Frozen shoulder, which causes pain and range of motion loss
affecting 9% of the population aged 25 to 64 year of age; currently
the only treatment for early stage is local steroid injection for
short-term relief. ATNF’s phase 2 clinical trials of a local
injection of anti-TNF are planned for Q3 this year.
- Fibrosis of the liver (NASH) commonly caused by nonalcoholic
fatty liver disease (NAFLD) affects an estimated 30% of the U.S.
population.
- Post-operative delirium/cognitive dysfunction (POCD) is a
serious postsurgical complication, and 180 has strong clinical
evidence for anti-TNF as a preventative therapy.
Building the Next Blockbuster Drug
180’s scientists have discovered that during surgery, especially
during emergency hip replacements or coronary artery bypass graft
(CABG) surgeries, TNF is released into the body and travels to the
brain where it causes certain areas of the brain to become
inflamed. POCD is a common and well-known postsurgical
complication, especially in the elderly. A severe decline in
cognitive function, mainly in memory and executive functions, can
be persistent, lasting a few days to a year or longer after
surgery, seriously diminishing quality of life. Some patients never
recover and end up in nursing homes. During or after surgery, TNF
can be released, which can cause dementia. There’s strong evidence
the body's inflammatory response to surgery plays an important role
in POCD onset, and anti-TNF therapeutics may well be the
solution.
Reports indicate more than 350,000 coronary
artery bypass procedures are performed in the country
every year and more than 300,000 hip
fractures occur annually in the U.S. alone. POCD
incidence is greatest after major cardiovascular surgery,
and estimated
incidence ranges from 30 to 80% during the first few weeks
postsurgery and up to 60% after three to six months. Research
initiatives have evaluated whether actions taken before, during and
after surgery can lessen the damaging effects of inflammation.
Administering anti-inflammatory agents before surgery may offer
substantial benefits, and 180 Life Sciences is in hot pursuit of a
preventive therapeutic regimen.
The 180 Life Sciences team has found that the trauma associated
with surgery leads to the release of inflammatory mediators. These
mediators, including TNF and Interleukin 1 beta (IL-1β), lead to
increased permeability of the blood brain barrier and inflammation
of critical parts of the brain, including the hippocampus, the part
of the brain involved in the formation of new memories and
associated with learning and emotions. Damage to this area leads to
cognitive decline.
180 Life Sciences is convinced its anti-TNF program can be used
to reduce or prevent POCD incidence. The company filed patent
claims that have been granted and licensed from Kennedy Trust, UK.
180 Life Sciences also intends to initiate a phase 2
trial of pre-operative anti-TNF therapeutics in hip fracture
surgery by Q4 2021 or early 2022 . depending on resolution of
th COVID epidemic, with a single dose of anti-TNF administered just
prior to surgery. If successful, 180’s novel approach could become
the standard of care to prevent POCD in coronary artery bypass
procedures, hip surgery and more. As a standard-of-care protocol,
the number of potential applications globally is significant and
could potentially lead to the next blockbuster drug from the
scientists at 180 Life Sciences.
Anti-Inflammatory Advocates
Johnson
& Johnson (NYSE: JNJ) is the largest and most
broadly based health-care company in the world and engages in the
research and development, manufacture and sale of products in the
health-care field. JNJ owns Remicade (infliximab), a blockbuster
several times over with approved use across a range of inflammatory
diseases. The founders of 180 Life Sciences discovered the anti-TNF
drug class that led to the development of Remicade and to a $4.9
billion merger between Centocor Biotech and JNJ.
AbbVie Inc. (NYSE:
ABBV) is a research-based biopharmaceutical company
engaged in the development and sale of pharmaceutical products.
With a focus on treating conditions such as chronic autoimmune
diseases, AbbVie owns Humira, an anti-TNF therapeutic and the
top-selling drug in the world. AbbVie’s Humira (adalimumab) reached
almost $20 billion in sales in 2018 and demonstrates the potential
of anti-inflammatory drugs to make mega-bucks.
Amgen
Inc. (NASDAQ: AMGN) is one of the
world’s leading biotechnology companies. The company focuses on
areas of high unmet medical need and leverages its expertise to
strive for solutions that improve health outcomes and dramatically
improve people's lives. Amgen has been at the forefront of
innovator biologic medicines for inflammation for more than 20
years and now has a pipeline rich in biosimilars that treat
inflammation. Amgen paid $13.4 billion in cash for Celgene’s
blockbuster anti-inflammatory drug, Otezla, which treats psoriasis
and psoriatic arthritis by regulating cellular inflammation.
Committed to creating high-quality medicines that meet real
needs, Eli
Lilly (NYSE: LLY) is a drug manufacturing company and
a leader in global health care. The company discovers, develops,
manufactures and markets products in its human pharmaceutical
product segment. The company recently announced a deal for Rigel
Pharmaceuticals’ autoimmune and inflammatory diseases treatment for
$960 million.
Anti-inflammatory drugs created by the scientists now at 180
Life Sciences have changed the lives of millions and generated
billions in sales revenue. All indications point to the scientists
at 180 Life Sciences being able to repeat past successes, with the
possibility of delivering the next generation of blockbuster
anti-inflammatory therapeutics.
For more information about 180 Life Sciences Corp., please visit
180 Life
Sciences Corp.
About NetworkNewsWire
NetworkNewsWire
(“NNW”) is a financial news and content distribution company, one
of 50+ brands within the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via InvestorWire to
reach all target markets, industries and demographics in the most
effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a full
array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024